3 unchanged sentences
(c) Director and Officer Trading Plans and Arrangements
−Removed: On June 6, 2023 , Randal W.
−Removed: Scott, Ph.D .
−Removed: , a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 16,000 shares of our common stock (the “June 6 Plan”).
−Removed: The June 6 Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and is expected to remain in effect until the earlier of (1) September 30, 2024 and (2) the date on which an aggregate of 16,000 shares of our common stock have been sold under such plan.
−Removed: On June 15, 2023 , Frank McCormick , Ph.D., a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 200,000 shares of our common stock (the “June 15 Plan”).
−Removed: The June 15 Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and is expected to remain in effect until the earlier of (1) September 19, 2024 and (2) the date on which an aggregate of 200,000 shares of our common stock have been sold under such plan.
+Added: On August 16, 2023 , Hannah A.
+Added: Valantine , a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 34,980 shares of our common stock (the “Trading Plan”).
+Added: The Trading Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and is expected to remain in effect until the earlier of (1) November 30, 2024 and (2) the date on which an aggregate of 34,980 shares of our common stock have been sold under such plan.
Exhibit Title
1 unchanged sentence
and Globe Merger Sub II, Inc.
−Removed: (incorporated by reference to Exhibit 2.1 to BridgeBio’s Current Report on Form 8-K filed with the SEC on October 6, 2020) .
+Added: (incorporated by reference to Exhibit 2.1 to BridgeBio’s Current Report on Form 8-K filed with the Securities Exchange Commission on October 6, 2020) .
January 26, 2021
16 unchanged sentences
January 29, 2021
−Removed: BridgeBio Pharma, Inc.
−Removed: Amended and Restated 2019 Inducement Equity Plan, effective February 10, 2023.
−Removed: Equity Distribution Agreement dated May 4, 2023, by and among the Company and Goldman Sachs & Co.
−Removed: LLC and SVB Securities LLC.
−Removed: Form of Restricted Stock Unit Award Agreement under BridgeBio Pharma, Inc.
−Removed: Amended and Restated 2019 Inducement Equity Plan (2023 Form).
−Removed: Filed herewith
−Removed: Form of Restricted Stock Award Agreement under BridgeBio Pharma, Inc.
−Removed: Amended and Restated 2019 Inducement Equity Plan (2023 Form).
−Removed: Filed herewith
−Removed: Form of Non-Qualified Stock Option Agreement under BridgeBio Pharma, Inc.
−Removed: Amended and Restated 2019 Inducement Equity Plan (2023 Form).
−Removed: Filed herewith
−Removed: Form of Restricted Stock Unit Award Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc.
−Removed: Stock Option and Incentive Plan (2023 Form).
−Removed: Filed herewith
−Removed: Form of Restricted Stock Award Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc.
−Removed: Stock Option and Incentive Plan (2023 Form).
−Removed: Filed herewith
−Removed: Form of Non-Qualified Stock Option Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc.
−Removed: Stock Option and Incentive Plan (2023 Form).
−Removed: Filed herewith
−Removed: Form of Non-Qualified Stock Option Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc.
−Removed: Stock Option and Incentive Plan for Board of Directors (2023 Form).
+Added: Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc., and the purchasers party thereto.
+Added: September 25, 2023
+Added: Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc.
+Added: and the purchasers party thereto.
+Added: September 25, 2023
+Added: Second Amendment, effective as of August 15, 2023, to the Exclusive (Equity) Agreement, by and between Eidos Therapeutics, Inc.
+Added: and the Board of Trustees of the Leland Stanford Junior University, effective as of April 10, 2016, as amended by Amendment No.
+Added: 1, effective September 25, 2017.
Filed herewith
23 unchanged sentences
Filed herewith
−Removed: # Indicates a management contract or any compensatory plan, contract or arrangement.
* This certification will not be deemed “filed”
1 unchanged sentence
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
+Added: Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BridgeBio Pharma, Inc.
−Removed: August 3, 2023
+Added: November 2, 2023
/s/ Neil Kumar
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 3, 2023
+Added: November 2, 2023
/s/ Brian Stephenson
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.